Amgen May 16, 2026 Amgen Inc stock (US0311621009): lungs cancer setback meets steady biotech cash flow - AD HOC NEWS
Amgen May 15, 2026 Alumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects - Fierce Biotech
Amgen May 14, 2026 Amgen stock (US0311621009): Biotech leader navigates patent cliffs and pipeline momentum - AD HOC NEWS
Amgen May 12, 2026 This Week’s Biopharma News: Amgen Deepens US Manufacturing Push - The Medicine Maker
Amgen May 10, 2026 Quantum firm hailed by Amgen tech leader as an ‘extraordinary platform’ plans IPO - Fierce Biotech
Amgen May 6, 2026 Biopharma Manufacturing Expands in the U.S.: Amgen, Lilly Double Down on Capacity and Next-Gen Production - BioPharm International
Amgen May 4, 2026 Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge? - 24/7 Wall St.
Amgen May 4, 2026 Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge? - Yahoo Finance
Amgen May 4, 2026 Amgen channels another $300M into US outlay, bolstering Puerto Rico biologics expansion - Fierce Pharma
Amgen May 2, 2026 Biopharma bites: Novo rebrands Rybelsus as the Ozempic pill, and Amgen trims its pipeline - FirstWord Pharma
Amgen May 1, 2026 Repatha sales help Amgen overcome Prolia biosimilar hits in 1st quarter - Fierce Pharma